NCT04387916 - A Study of KC1036 in Patients with Advanced Solid Tumors | Biotech Hunter

Enrollment

207

Participants

Timeline

Start Date

September 4, 2020

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Advanced Solid Tumors

Interventions

DRUG

KC1036

Part 1: Dose-escalation phase , KC1036 10mg\~80mg, consists of 5 Cohorts. Part 2: Dose-expansion phase, consists of 3\~4 Cohorts based on part 1. Part 3:RP2D-extension phase, Recommended dose of KC1036 based on part 1and part 2.

Trial Locations (3)

Unknown

RECRUITING

ChongQing University Cancer Hospital, Chongqing

RECRUITING

The First Affiliated Hospital of Hainan Medical University, Haikou

RECRUITING

West China Hospital, Chengdu

All Listed Sponsors

lead

Beijing Konruns Pharmaceutical Co., Ltd.

INDUSTRY